Navigation Links
Frost & Sullivan's 2009 Excellence in Healthcare Awards Banquet Honours Industry's Top Performers
Date:10/12/2009

that leads to improvements in the Healthcare systems for every strata of the population, sophistication of hospitals, improved IP regulations and the greater need for superior commercialisation plans. All in all, China promises to be the biggest growth opportunity for the Healthcare companies in the west, irrespective of their size."

Following this address was the evening's highlight - the awards presentation recognising outstanding performers in the healthcare arena over the past year:

  • Touch Bionics - 2009 European Bionic Limbs Hot Investment Opportunity Award
  • Ziehm Imaging - 2009 European Mobile C-Arms Business Development Strategy Leadership Award
  • ERGONEX Pharma - 2009 European Orphan Diseases Entrepreneurial Company Award
  • Mennen Medical Ltd - 2009 European Patient Monitoring Technology Leadership of the Year Award
  • TCLAND EXPRESSION - 2009 European Biomarker Discovery and Development Entrepreneurial Company of the Year Award
  • TCLAND EXPRESSION - 2009 European Gene Expression Biomarkers Technology Innovation Award
  • Cegedim Dendrite - 2009 World LifeSciences-IT Market Leadership Award
  • InterSystems - 2009 European Hospital Information System Customer Value Leadership Award
  • Anoto - 2009 European Care Management Systems Industry Innovation & Advancement Award
  • Viatronix Incorporated - 2009 European Medical Imaging Emerging Company of the Year Award
  • Phillips Healthcare - 2009 European Fluoroscopy Product Quality Leadership Award

The Frost & Sullivan Healthcare Awards Banquet honoured Europe's best healthcare companies for their achievements over the course of this year. At a time of global recession and recovery, these award winners have devised strategies to stay on top of their markets and realise competitive excellence.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enabl
'/>"/>

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award
2. Emergence of Newer Drug Classes to Treat Diabetes and Co-morbidities Key to Market Expansion, Reveals Frost & Sullivan
3. PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group
4. Growing Awareness and Increased Investments Lead to Growth of Biotechnology Applications in the Food & Beverage and Dietary Supplements Sector, Reveals Frost & Sullivan
5. Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities
6. SyntheMed Receives Frost & Sullivan Health Innovation Award Nomination
7. Government Mandates Create Guaranteed Market for Bio-Fuel, Says Frost & Sullivan
8. Frost & Sullivan Recognizes Cisbio Bioassays for Technology Innovation
9. Frost & Sullivan: Lower Import Duties and Rising Customer Demand to Boost Russian Electronics Manufacturing Market
10. Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market
11. The Global Active Pharmaceutical Ingredients (API) Market: A Frost & Sullivan Briefing on Changing Dynamics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... (PRWEB) October 24, 2014 According ... Market by Data Center Types (Colocation, Enterprise, Telecom), ... Types (Tier 1, Tier 2, Tier 3, Tier ... MarketsandMarkets, defines and segments the Data Center Construction ... and forecasting of revenues. This research report also ...
(Date:10/25/2014)... SonaCare Medical, LLC, leader in minimally ... that its Board of Directors has appointed Dr. ... and member of the Board effective immediately. In ... responsibilities within the company, including further developing the ... manufacturing and finance. , Dr. Carol joined ...
(Date:10/25/2014)...  RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" or ... International Symposium on Thymosins in Health and Disease in ... "When thymosin beta 4 (TB4) linked with rhodamine (a ... in a rodent model of stroke, it was visualized ... (the functional tissue of the brain).   The leakage of ...
(Date:10/22/2014)... , Oct. 22, 2014 Research ... the "Global DNA Diagnostics Market (Product types, ... Share, Global Trends, Company Profiles, Demand, Insights, Analysis, ... 2020" report to their offering. ... (products, applications, techniques, end users and Geography) Global ...
Breaking Biology Technology:Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3
... 28, 2011 TriLink BioTechnologies, Inc. (TriLink) and Lucigen ... signed a licensing agreement for the use of TriLink,s ... MasterMix. TriLink,s CleanAmp™ dNTPs are an innovative ... standard dNTPs in a PCR assay with CleanAmp™ dNTPs, ...
... SILVER SPRING, Md., July 28, 2011 United Therapeutics Corporation ... for the quarter ended June 30, 2011. "I,m ... quarter, as well as the very good operating results we ... Executive Officer. "We remain on track to reach our 2011 ...
... Mass., July 27, 2011 SomaLogic, Inc. ... today that they have entered into an ... specific SOMAmers as critical and unique reagents ... acid amplification and polymerase chain reaction (PCR) ...
Cached Biology Technology:TriLink BioTechnologies, Inc. Announces License Agreement with Lucigen Corporation 2United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 7Agreement Between SomaLogic and New England Biolabs Enables the Use of SOMAmer Technology for the Optimization of Multiple PCR Products 2
(Date:10/16/2014)... (October 16, 2014) – Post-menopausal women experienced improvements ... hormone levels or genital bleeding, after 12 weeks ... investigational fermented soy germ-based nutritional supplement previously shown ... a new peer-reviewed pilot study reported in a ... annual scientific meeting. , "These data documented ...
(Date:10/15/2014)... , Oct. 15, 2014 Sandata ... for home and community-based care, today announced it ... implementing Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™) ... is a home health company founded in 1996 ... . The study details ...
(Date:10/15/2014)... a non-traditional biophysics textbook and it describes how life ... of discovery into biological systems and provides an understanding ... is about how our genes make proteins that control ... cells in an organism. It quantifies the principles of ... be found on both large and small scales. The ...
Breaking Biology News(10 mins):S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2Sandata Announces Case Study with Quality Care Services, Inc. 2New book about life as seen from physics 2
... NVIDIA CUDA Teaching Centre in Canada. The ... electrical and computer engineering students how to tap ... units (GPU) and use them in computationally demanding ... that enables dramatic increases in computing performance for ...
... successful initial testing of a new form of methotrexate ... nose drops rather than injected. It shows promise as a ... appears in ACS, Molecular Pharmaceutics , a bi-monthly journal. ... is difficult to treat, partly because current anticancer drugs have ...
... major risk factor for disease, much of the threat ... a cluster of risk factors related to diabetes and ... many of these risk factors. However, many people struggle ... the University of Missouri have found that people who ...
Cached Biology News:McMaster, NVIDIA establish first CUDA Teaching Centre in Canada 2Putting on the pounds after weight loss? Hit the gym to maintain health gains 2
... siSolutions siRNA Custom Synthesis ... effective duplex RNA to knockdown ... 21-mers (19 RNA base pairs ... recently-published 27-mers, or other lengths ...
Alexa Fluor 647 anti-mouse Qa-2...
...
Alexa Fluor 647 anti-mouse Qa-2...
Biology Products: